The field of cancer treatment is on the cusp of a breakthrough with Myricx Bio’s innovative approach to antibody-drug conjugates (ADCs). These novel therapies promise to significantly enhance the effectiveness of cancer treatment by precisely targeting cancer cells while sparing healthy tissues.
Myricx Bio, a UK-based biotech firm, is making headlines with its pioneering development of a new class of ADC payloads. These payloads are based on N-Myristoyltransferase inhibitors (NMTi), which have shown remarkable efficacy in preclinical trials against several solid tumors.
Background on ADCs and NMTi
ADCs Overview: Antibody-drug conjugates (ADCs) represent a cutting-edge class of therapeutics designed to deliver potent cytotoxic drugs directly to cancer cells.
